Compare Ishares Msci Italy ETF (EWI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Zoetis Inc — how do they compare? Ishares Msci Italy ETF trades at $63.15, while Zoetis Inc trades at $73.5 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Ishares Msci Italy ETF pays none, and Ishares Msci Italy ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| EWI | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $156.76 |
52-Week Low | $50.31 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI trades at $63.165, showing minimal daily movement with a slight decline of 0.01%. The technical outlook is bullish based on moving averages, though oscillators signal neutrality with RSI readings above 80 indicating potential overbought conditions. Recent news highlights Italy's market strength with EWI hitting a 52-week high in June 2026, driven by improving industrial data and recovery narrative. A dividend of $1.17 is scheduled for June 2026, providing income appeal.
The stock benefits from positive European market sentiment and Italy's economic recovery, but faces risks from ECB rate policy and energy price volatility. Technical indicators suggest near-term consolidation may be needed given overbought signals. Long-term prospects appear favorable if Italy's economic momentum continues, though investors should monitor ECB decisions and energy market developments closely.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
